Effect of growth hormone on aging connective tissue in muscle and tendon - gene expression, morphology and function following immobilization and rehabilitation by Boesen, Anders Ploug et al.
Effect of growth hormone on aging connective tissue in muscle and tendon:
gene expression, morphology, and function following immobilization
and rehabilitation
A. P. Boesen,1 K. Dideriksen,1 C. Couppé,1,5 S. P. Magnusson,1,5 P. Schjerling,1 M. Boesen,3 P. Aagaard,4
M. Kjaer,1 and H. Langberg1,2
1Department of Ortopaedic Surgery M, Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, and Center for Healthy
Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Department of Public
Health, CopenRehab, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;
3Department of Radiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 4Institute of Exercise Physiology
and Clinical Biomechanics, SDU Muscle Research Cluster (SMRC), University of Southern Denmark, Odense, Denmark;
and 5Department of Physical Therapy, Bispebjerg Hospital, Copenhagen, Denmark
Submitted 24 September 2013; accepted in final form 11 November 2013
Boesen AP, Dideriksen K, Couppé C, Magnusson SP, Schjer-
ling P, Boesen M, Aagaard P, Kjaer M, Langberg H. Effect of
growth hormone on aging connective tissue in muscle and tendon:
gene expression, morphology, and function following immobilization
and rehabilitation. J Appl Physiol 116: 192–203, 2014. First published
November 14, 2013; doi:10.1152/japplphysiol.01077.2013.—It is un-
known whether loss in musculotendinous tissue during inactivity can
be counteracted by growth hormone (GH), and whether GH accelerate
rehabilitation in aging individuals. Elderly men (65–75 yr; n  12)
had one leg immobilized 2 wk followed by 6 wk of retraining and
were randomly assigned to daily injections of recombinant GH
(rhGH; n  6) or placebo (Plc; n  6). Cross-sectional area (CSA),
muscle strength (MVC), and biomechanical properties of m. quadri-
ceps and patellar tendon were determined. Muscle and tendon biopsies
were analyzed for gene expressions (mRNA) of collagen (COL1A1/
3A1) and insulin-like growth factors (IGF-1Ea/Ec). Fibril morphology
was analyzed by transmission electron microscope (TEM). In tendon,
CSA and biomechanical properties did not change following immo-
bilization, but an increase in CSA was found after 6 wk of rehabili-
tation in both groups. The changes were more pronounced when GH
was injected. Furthermore, tendon stiffness increased in the GH
group. Muscle CSA declined after immobilization in the Plc but not in
the GH group. Muscle CSA increased during retraining, with a
significantly larger increase in the GH group compared with the Plc
group. Both a time and a group effect were seen for IGF-1Ea/Ec and
COL1A1/3A1 mRNA expression in muscle, with a difference be-
tween GH and Plc. IGF-1Ea/Ec and COL-1A1/3A1 mRNA expres-
sion increased in muscle following immobilization and retraining in
subjects receiving GH, whereas an increase in IGF-1Ec mRNA
expression was seen in the Plc group only after retraining. In conclu-
sion, in elderly humans, GH seems to have a matrix stabilizing effect
during inactivity and rehabilitation by stimulating collagen expression
in the musculotendinous tissue and increasing tendon CSA and
stiffness.
growth hormone; connective tissue; tendon; skeletal muscle; inactiv-
ity
HUMAN AGING IS ASSOCIATED with a reduction in skeletal muscle
mass (28, 34, 56), and human skeletal muscle force output
drops 1% per year after the age of 50 (72). It is also known
that physical activity is reduced with aging and that inactivity
causes a loss in skeletal strength (6, 18, 56, 73). To what extent
the loss in skeletal muscle with aging is a direct effect of the
age-related decrease in activity, whether it is due to aging per
see, or whether it is a mix of the two is at present unknown.
Elderly individuals are in general more prone to periods of bed
rest due to a higher degree of comorbidity and hospitalization
(22, 48, 56), which may further accelerate the general loss of
skeletal muscle mass and muscle strength (6, 18, 25, 52, 73).
An accelerated loss of muscle mass and strength could thus be
detrimental for the functional capacity and increase, e.g., the
risk for fall injuries (27, 52). This underlines that maintenance
of muscle mass and function in older individuals, especially
during periods of inactivity, is of vital importance. Despite this,
the effect of inactivity on skeletal muscle has mainly been
investigated in young subjects (6, 10, 18, 26) and less fre-
quently in elderly subjects (33, 41, 73). Recent short-term
inactivity studies in the elderly have shown a reduced ability to
regain lost muscle mass during recovery compared with young
individuals (33, 73).
The tendon tissue may also be influenced by transient
periods of immobilization or reduced loading. Animal studies
have shown a decline of the mechanical properties of the
tendon (2, 50, 65), whereas others suggest the opposite (3, 24).
Recent studies in humans have shown that short-term inactivity
has no major morphological effect on tendon size itself (17, 18,
69) but rather seems to decrease tendon biomechanical prop-
erties dramatically (17, 18, 69) and reduce collagen synthesis
(14, 19).
The growth hormone (GH)/IGF-1 axis is known to play a
central role in the regulation of human collagen turnover in
musculotendinous tissue (21), with IGF-1 stimulating collagen
formation in both tendon and skeletal muscle (1, 1, 59). IGF-I
may also inhibit muscle protein degradation, which is an effect
of potential importance during immobilization periods when
there is a net muscle protein loss (80). Aging is associated with
a gradual loss of the GH/IGF-I axis activity, and plasma levels
of IGF-I decline with age (46, 64, 81). In fact,30% of elderly
men have IGF-1 levels below the reference range of young
adults (46, 64). This decline in plasma IGF-1 levels is associ-
ated with a change in body composition, with increased body
fat and a loss in muscle mass (35, 62). Administration of GH
to elderly has been shown to increase plasma IGF-1 levels (49)
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and to cause gains in lean body mass (fat-free mass) (63).
However, whether GH supplementation in elderly humans can
counteract the loss in musculotendinous tissue quality and
mass during inactivity or accelerate the effect of subsequent
rehabilitation remains unknown. Studies on GH supplementa-
tion have generally failed to demonstrate any myofibrillar
anabolic effect in the elderly (44, 74, 75). Interestingly, how-
ever, short-term treatment with GH or IGF-I in elderly women
has been shown to induce elevated muscle protein synthesis
and net whole body protein synthesis, respectively (11). In
young humans, upregulation of skeletal muscle IGF-I expres-
sion is associated with increased collagen protein synthesis
(20). These findings indicate a coupling between local IGF-I
expression and collagen formation in human skeletal muscle.
In the present study, we hypothesize that systemic GH
supplementation in elderly humans, via an increase in the local
IGF-1 level, will stimulate collagen expression of connective
tissue of both the skeletal muscle and tendon tissue, and
thereby affect the maintenance of connective tissue (collagen)
and biomechanical properties of tendon during short-term in-
activity and accelerate the aforementioned parameters during
rehabilitation. Thus the aim of the present study was to inves-
tigate whether GH supplementation exerts a positive effect on
the musculotendinous tissue in elderly humans during periods
of short-term immobilization and rehabilitation.
METHODS
Study Design
Subjects. Twelve healthy, physically untrained elderly men (65–80
yr) with a body mass index between 19 and 30 were recruited for this
study. All subjects underwent medical evaluation before participation,
including a survey of their medical history and a physical examina-
tion, and all subjects included were healthy nonsmokers, and none
took any kind of prescribed medication that affected skeletal muscle
or tendon function. Furthermore, all subjects had no known serious
injuries of their lower extremities. The study design was a double-
blinded, randomized, placebo-controlled trial. The study (H-4-2010-
010) was approved by the local Ethics Committee of Region Copen-
hagen in accordance with the Helsinki declaration. All subjects were
informed of the risks associated with the study and gave their written,
informed consent.
Intervention protocol. All participants were subjected to 2 wk of
unilateral (randomly selected limb) lower limb cast immobilization
from the hip to the ankle followed by 6 wk of supervised unilateral
strength training (3 times/wk). All measurements described below
were conducted at baseline before the immobilization procedure (Pre),
after 2 wk of immobilization (Post immob), and again during reha-
bilitation (after 2 and 6 wk of heavy resistance training). Measure-
ments in the training period were always performed with a “wash-out
period” of 48 h after the last training session (Fig. 1).
rhGH administration. Subjects were randomly assigned in a dou-
ble-blinded fashion to receive either rhGH (Norditropin, Novo Nor-
disk, Denmark) (rhGH; n  6) or placebo (Plc; n  6). rhGH/Plc was
administered by daily subcutaneous injection in the proximal lateral
part of the thigh (immobilized leg) for the 8-wk intervention period.
rhGH dosage was 33.3 g·kg1·day1 the first week, and if there
were no signs of side effects the dosage was increased to 50 g·kg1·
day1 the remaining 7 wk. After detailed instructions, the subjects
were able to perform the injections themselves at home. The partici-
pants visited the institute once every week throughout the intervention
to ensure no side effects had occurred. If side effects were present
(pitting leg edema, carpal tunnel syndrome, trigger fingers, weight
gain or transient atrial fibrillation from fluid retention), the rhGH
dosage was adjusted to a tolerable concentration. If possible thereaf-
ter, the dose was gradually increased again up to the intended dosage:
50 g·kg1·day1. Subjects performed the injections before bedtime,
and blood samples were drawn early the next day during follow-ups.
Of the six subjects receiving rhGH, two subjects experienced mild
side effects (both demonstrated mild carpal tunnel syndrome, and one
of these trigger fingers), and the rhGH dose was reduced from 50
g·kg1·day1 to 33 g·kg1·day1 in these subjects until all side
effects disappeared (7 days). Subsequently, the dose was increased
again to 50 g·kg1·day1 with no discomfort.
Immobilization protocol. Immobilization was done for 2 wk using
a lightweight fiber cast applied from just above the malleoli to just
below the groin, which in other studies has proven to induce muscle
atrophy in short-term immobilization studies involving elderly indi-
viduals (73). The cast was positioned in 50° of knee joint flexion to
minimize walking ability using the casted limb, and the subjects were
carefully instructed to perform all activities on crutches, to abstain
from ground contact, and to avoid any contractile quadriceps activity
in the immobilized leg. During the 2 wk of immobilization, the
subjects were contacted every second day by mail or phone and were
carefully instructed to do passive movements with the ankle joint
(venous pump exercises) several times a day to prevent formation of
deep venous thrombosis (DVT). Furthermore, to reduce the potential
risk of DVT, all subjects took acetylsalicylic acid (ASA) tablets (75
mg/day) during the 2 wk of immobilization.
Rehabilitation procedure. After removal of the cast, the subjects
received rehabilitation training for 6 wk, in three sessions per week
(18 training sessions in total). The retraining protocol was a super-
vised, unilateral strength training program focusing on the immobi-
lized leg only, which has previously proven to elicit increases in
muscle size and maximal muscle strength in elderly individuals (73).
After a 5-min warm-up on a stationary bike, the subjects performed
supervised knee extension and leg press exercise. Training intensity
and volume were 3–4 sets  12 repetitions [15 repetitions maximum
2 wks
Including elderly men
- medical and physical  
examination
- blood samples 
2 wks 4 wks
Control leg Control leg (no training)
One leg immobilized Immobilized leg (re-training 3 times/wk)
48 hours after training session no. 6 48 hours after training session no. 18 
Baseline Post immob. 2 wks training 6 wks training
Fig. 1. Study design following 2 wk of immobilization and 6 wk of retraining in elderly men (n  12) with either recombinant human growth hormone (rhGH;
n  6) or placebo (n  6). Measurements performed at baseline after 2 wk of immobilization and again after 2 and 6 wk of retraining: blood samples, MRI scan
[muscle and tendon cross-sectional area (CSA)], maximal isometric muscle strength, tendon bimechanical properties, biopsies (muscle and tendon; tendon biopsy
was not performed after 2 wk of retraining).
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(RM)] in week 1, 4 sets  10 repetitions (12 RM) in weeks 2–4, and
4 sets  8 repetitions (10 RM) in weeks 5–8. Training loads were
adjusted on a weekly basis using 5-RM testing.
Measurements
Body composition. Dual-energy X-ray absorptiometry (Lunar DPX,
version 3.6Z software) was used to determine whole body composi-
tion and percent body fat at baseline and again after 8 wk of rhGH or
Plc administration. The same investigator (K. Dideriksen) performed
and analyzed all scans using the extended research analysis software
provided by Lunar. Total and regional scans were divided into three
compartments: lean body mass (LBM), fat mass (FM), and bone
mineral content (BMC).
Skeletal muscle cross-sectional area. To assess anatomical skeletal
muscle cross-sectional area (CSA), all participants were scanned in a
1.5-T Philips Intera (Eindhoven, Holland) or a General Electric (GE)
Signa Horizon MRI scanner using the following protocol. With the
subject in the supine position and both limbs extended and relaxed
using the body array coil, a scout localizer centered mid-femur was
performed to control that the femurs and knee joints were included in
the scanners field of view (FOV; 48 cm). Dependent on the femur
length of the subject, seven to eight T1-weighted (T1w) axial scans of
the femur (TE: 17; TR; 500; matrix: 864  864; FOV: 4,200) with a
slice thickness of 10 mm and an interslice gap of 50 mm was
performed. The first slice was always positioned just below the femur
condyles, where the tibia plateau was visible to ensure the same scan
position between examination time points. Quadriceps muscle CSA
was analyzed as described in detail elsewhere (73). The axial slice
equivalent to 50% of the femur length was used to calculate the CSA,
and the measurements were performed three times by a blinded,
trained person using the imaging software Osirix 2.7.5 (Osirix Imag-
ing Medical, Geneva, Switzerland). The mean value of the three
measurements was used as the result, and the coefficient of variation
for acceptance between measurements was set to 2.5%.
Tendon CSA. The patellar tendon was scanned in the same 1.5-T
MRI scanner as above with the patient supine using a dedicated knee
coil using an axial and sagittal T1w turbo spin echo sequence (TE: 17;
TR: 500; matrix: 512  512; FOV: 150 mm; slice thickness: 3 mm).
The knee was slightly flexed (12%) due to the build-in supportive
pillow in the coil, which ensured removal of slack in the patellar
tendon. The axial slices of the patellar tendon were positioned orthog-
onal to the length in the sagittal plane covering the distal patellar pole
to the tibial insertion. The procedure for analyzing the patellar tendon
has been described in detail elsewhere (16, 40). In brief, patellar
tendon CSA was measured using the axial slice just distal to the
patellar insertion, and the slice just proximal to the tibia insertion and
midway between these two sites, respectively (16, 40). The patellar
tendon length was obtained by measuring the distance from the most
dorsal insertion part at the patella apex to the dorsal insertion on the
tibia. Patellar tendon CSA and length were manually outlined by a
blinded examiner using the imaging software Osirix 2.7.5 (Osirix
Imaging Medical), as described in detail elsewhere (16, 40). All
measurements were performed three times by the same observer, who
was blinded to the chronological MRI time points and treatment
groups (GH or Plc). The mean value of these measurements was used
as the result, and the coefficient of variation for acceptance between
duplicate measurements was set to 2.5%.
Maximal muscle strength and mechanical properties of patellar
tendon. Details of the maximal voluntary contraction (MVC) mea-
surement and analysis of tendon mechanical properties, including
reliability assessments, have been reported previously (16, 40). With-
in-day correlation coefficient and typical error percent results for
repeated measures were 0.95 and 9.9% for tendon stiffness, 0.97 and
5.5% for tendon strain, and 0.94 and 9.4% for Young’s modulus. The
subjects were asked to refrain from strenuous exercise 48 h before the
experiments. The subjects performed a 5-min warm-up on a stationary
bike to ensure a standardized preconditioning of the tendon before
testing. Subsequently, the subjects were seated in a custom-made rigid
chair with both hips and knees flexed to an angle of 90°. A leg cuff,
which was connected to a strain gauge (Noraxon) through a rigid steel
rod perpendicular to the lower leg, was mounted on the leg just above
the medial malleolus. A Hitachi EUB-6500 ultrasound scanner (Hi-
tachi Medical, Tokyo, Japan) equipped with a 10-MHz, 100-mm-long,
linear array B-mode transducer (Hitachi, model EUP-L53L) was fitted
into a custom-made rigid cast that was secured to the skin above the
patellar tendon in the sagittal plane. The ultrasound probe and cast
were positioned so that the distal patella, the entire patellar tendon,
and the proximal tibia were all visible within the field of view
throughout the performed isometric ramp contractions (see below).
The subjects performed four to five slow isometric ramp contrac-
tions of the knee extensor by applying gradually increasing force until
reaching maximum force (MVC) over a 10-s period, during which
patellar tendon displacement and knee extension force were synchro-
nously measured. All measurements were performed unilaterally (im-
mobilized limb). Maximal muscle strength of the quadriceps muscles
(MVC) was determined as the peak knee extensor moment produced
during the 10-s ramp contraction. During the ramp contractions,
ultrasound S-VHS video images were sampled at 25 Hz using frame-
by-frame capturing software (Matrox Morphis Dual frame grabber
and Matrox Imaging Library software, Matrox Electronic Systems,
Montreal, Canada). Custom-made, frame-by-frame tracking software,
using a pyramidal implementation of the Lukas-Kanade optical flow
estimation, was used to assess the tendon deformation from the
ultrasound videos. The accuracy and reproducibility of this tracking
software have previously been assessed (47). A trigger signal (Pulse
generator, PG 58AA, GouldAdvance, Essex, UK) initiated recording
of force and ultrasound video, thus allowing for subsequent synchro-
nization of all recorded data during the ramp contractions. The
external tibia moment arm was measured (from the leg cuff to the
lateral epicondyle of the knee) to calculate the knee extensor moment
(M  force  moment arm). The force applied to the patellar tendon
was calculated by dividing the measured knee extensor moment by the
internal patellar tendon moment arm, which was estimated from
individually measured femur lengths (16, 40). Tendon deformation
was defined as the change in distance between the patellar apex and
tibia (16, 40). Tendon stress was calculated by dividing tendon force
with the average tendon CSA (mean of proximal, middle, and distal
CSA from MRI). Tendon strain was calculated as the change in length
normalized relative to initial resting tendon length. Polynomial func-
tions (second order) were fitted to each single force-deformation
curve. Tendon stiffness (	 force/	 deformation) and Young’s modu-
lus (	 stress/	 strain) were calculated at the final 10% of the
force-deformation and stress-strain curves, respectively.
All structural measurements [quadriceps muscle CSA and patellar
tendon CSA, maximal muscle strength (MVC), and patellar tendon
mechanical properties] were performed on both sides at baseline (Pre)
and after 6 wk of strength training while only in the immobilized leg
after immobilization (Post immob) and at 2 wk of retraining.
Tissue biopsy sampling. Muscle biopsies were obtained at baseline,
just after immobilization, and again after 2 and 6 wk of rehabilitation.
Tendon biopsies were taken at baseline at the control leg and at the
immobilized leg after the immobilization period to avoid potential
re-biopsy effects, and again from both sides after 6 wk of retraining.
After initiating the present study, we analyzed biopsies from another
study and found that a 6-wk “washout period” is not enough to avoid
a repeated biopsy effect on mRNA for several growth and matrix
factors (like IGF-I and COL) (20). Based on these data, the biopsies
from the 6 wk of retraining were not used in the statistical analysis of
time or group interactions. The muscle and tendon biopsy procedures
have been described in detail elsewhere (30, 38). In brief, the sample
sites were prepared after sterilization with local anesthetics (lidocaine,
1%). Muscle tissue was taken from the vastus lateralis muscle using
a 5-mm Bergström needle with suction (7), and tendon tissue was
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taken from the patellar tendon (Bard Magnum Biopsy Instrument,
C.R. Bard, Covington, GA) with a 14-G needle (55). The total wet
weight of the muscle sample was 80–100 mg, and the total wet weight
of the tendon sample was 8–10 mg. The biopsy samples were cleared
of external adipose tissue and blood, frozen in liquid nitrogen, and
stored at 80°C for subsequent analysis.
Hormone measurements. Blood samples drawn from the antecubi-
tal vein were separated (3,200 g, 4°C), and serum was stored at
80°C. Serum IGF-I (sIGF-I) concentrations were determined in
duplicates with GH ELISA, RMEE022 (Biovendor, Heidelberg, Ger-
many), and IGF-1 ELISA, RMEE20 (Biovendor).
sIGF-1 was used as a marker for the effect of GH supplementation
since rhGH injected subcutaneously (sGH) has a relative short half-
time (2–4 h) compared with sIGF-1 (days) and since normal endog-
enous human GH is secreted in 6–12 discrete pulses per day, resulting
in fluctuating values.
Muscle and tendon mRNA measurements. Tendon and muscle were
homogenized in TriReagent (Molecular Research Centre, Cincinnati,
OH) using a bead-mixer with steel beads (Biospec Products, Bartles-
ville, OK). Following homogenization, bromo-chloropropane (Molec-
ular Research Centre) was added to separate the samples into an
aqueous and an organic phase. Glycogen was added to the tendon
samples to improve RNA precipitation. Following isolation of the aque-
ous phase, RNA was precipitated using isopropanol, washed in ethanol,
and dissolved in RNase-free water. All tissue samples were weighed
before RNA extraction. Muscle RNA concentrations were determined by
spectroscopy, and tendon RNA concentrations were determined using
RiboGreen assay (Molecular Probes, Eugene, OR). Good muscle RNA
quality was ensured by gel electrophoresis (tendon samples had too
little RNA for gel electrophoresis). The amount of mRNA for collagen
I (COL1A1), collagen III (COL3A1), IGF-IEa, IGF-IEc, lysyl oxidase
(LOX), MMP-2, MMP-9, decorin, GAPDH, and RPLP0 was deter-
mined and measured with reverse-transcription, real-time PCR, as
described in detail elsewhere (20). Primer sequences are given in
Doessing et al. (20), except for LOX (CGC TGT GAC ATT CGC
TAC ACA GGA C, CAT TGG GAG TTT TGC TTT GCC TTC T),
MMP-2 (CCG CCT TTA ACT GGA GCA AAA ACA, TTG GGG
AAG CCA GGA TCC ATT T), MMP-9 (AGC GAG GTG GAC CGG
ATG TT, AGA AGC GGT CCT GGC AGA AAT AG), and decorin
(GGT GGG CTG GCA GAG CAT AAG T, TGT CCA GGT GGG
CAG AAG TCA). RPLP0 was used for normalization. To validate
RPLP0 as an unregulated mRNA useful for normalization, we also
measured GAPDH. Ideally, the ratio between GAPDH and RPLP0
should be one in all groups. Unfortunately, after immobilization, there
was a slight decrease in GAPDH relative to RPLP0 in the placebo
group, indicating that either GAPDH decreased or RPLP0 increased at
that specific time point (Fig. 2). It is not possible to distinguish
between the two possibilities, but during immobilization we find it
more likely that the metabolic marker GAPDH decreased than protein
synthesis (RPLP0) increased, for which reason RPLP0 was chosen for
normalization.
Transmission electron microscopy imaging and stereology analysis
(tendon). The procedure from the tendon biopsies for making trans-
mission electron microscopy (TEM) images for stereologic analyses
of tendon fibrillar morphology has previously been described in detail
(39). In brief, after tendon biopsies were rinsed in 0.15 M sodium
cacodylate buffer (pH 7.2), all specimens were fixed in 1% OsO4 in
0.15 M sodium cacodylate buffer (pH 7.2) for 2 h and subsequently
dehydrated in ethanol, transferred to propylene oxide, and embedded
in EPON resin 828/862 mix (Hexion Specialty Chemicals, Rotterdam,
The Netherlands), according to standard procedures. After this, sec-
tions were cut using a Reichert-Jung Ultracut E microtome. Semi-thin
sections, for preanalytic evaluation of the samples, were stained with
toluidine blue and visualized (digital images) using a Nikon Coolpix
990 (Nikon Nordic ABl, København, S. Denmark). When proper
condition and orientation of the sample within the EPON block were
confirmed, ultra-thin sections were cut and collected on a one-hole
copper grid with Formvar supporting membranes and stained with
uranyl acetate and lead citrate. From each biopsy sample cross
section, a simple random sample of 10 digitized TEM images was
obtained from the intercellular space.
The stereologic analyses of the TEM images were completed on a
computer monitor, onto which the digitized TEM images were merged
with a graphic representation of the stereologic test system (C.A.S.T.-
grid software, The International Stereology Centre at Olympus). The
collagen fibrils were counted and measured using a magnification of
210,000. The counting frames covered 3% of the TEM image area,
and the TEM images covered 0.5% percent of the biopsy sample
cross section (5 m2). On average, 455 fibrils (range, 150–1,209)
were analyzed per cross section. Fibril area was calculated from
measurements of fibril diameter. Fibril diameter was measured as the
largest diameter perpendicular to the longest axis of each fibril cross
section, thereby eliminating the influence of sectioning angle. The
fibril density was expressed as the absolute number of fibrils per
square micrometer, and the fibril volume fraction states the area
occupied by fibrils within the sample area. A single experienced and
blinded investigator (J. O. Larsen) performed all stereological analy-
ses.
Statistics Analysis
Data were analyzed in SigmaPlot version 11 using two-way,
repeated-measures ANOVA with Student-Newman-Keuls post hoc
test. Data are presented as means 
 SE. mRNA data from RT-qPCR
and serum IGF-1 (sIGF-1) levels were log transformed before the
statistical analysis and presented as geometric means 
 back-trans-
formed SE. An alpha level of P  0.05 was considered significant.
Due to technical problems, biomechanical data could only be
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Fig. 2. Muscle and tendon GAPDH mRNA expression after 2 wk of immo-
bilization and 6 wk of retraining in elderly men (n 12) with either rhGH (n
6) or placebo (n  6). A: GAPDH mRNA (muscle). B: GAPDH mRNA
(tendon). Data are geometric means 
 SE. *Significant time effect difference
compared with baseline (both groups; P  0.05).
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All 12 participants completed the study and complied with
all procedure in regard to rhGH/Plc administration according to
diaries and sGH/IGF-1 measures, immobilization, and training
sessions.
At baseline, there was no significant difference between the
two groups in age (means 
 SE: GH: 72.5 
 2.2 yr; Plc:
70.2 
 3.6 yr); height (GH: 177 
 2 cm; Plc: 177 
 2 cm),
weight (GH: 76.0 
 2.4 kg; Plc: 79.9 
 4.4 kg), or body mass
index (23.5 
 0.7 kg/m2; Plc: 24.1 
 3.4 kg/m2).
Body Composition
Body weight (BW), total fat mass (FM), or total lean body
mass (LBM) remained stable throughout the study in the Plc
group (Table 1). In the GH group, although BW was unchanged,
a decrease in FM was observed along with an increase in LBM
(baseline vs. post-intervention, P  0.05; Table 1).
sIGF-1
As a result of the rhGH supplementation, a time and group
interaction was seen for sIGF-1 (P  0.001; Fig. 3). There
were no significant differences between groups in sIGF-1 at
baseline. However, sIGF-1 increased approximately fivefold
during immobilization, and an approximately fourfold increase
was maintained during retraining in the GH group, with no
changes observed in the Plc group (Fig. 3).
Tendon CSA and Biomechanical Properties
A time effect and a group interaction were demonstrated for
patellar tendon CSA (P  0.05), with no group differences for
patellar tendon CSA before immobilization (baseline) or dur-
ing immobilization (Fig. 4A). However, patellar tendon CSA
increased in both groups during retraining compared with
baseline (P  0.05), with a significantly larger increase in the
GH group compared with the Plc group after 6 wk of retraining
(GH: 7.7 
 1.1% vs. Plc: 2.9 
 1.1%; P  0.05; Fig. 4A).
Patellar tendon stiffness revealed no overall time effect, but a
group interaction was seen (P 0.05). During immobilization,
no changes in tendon stiffness emerge within any of the
groups, but, after retraining, tendon stiffness was lower in the
Plc group compared with the GH group, with a significant
difference between groups after 6 wk of retraining (P  0.05;
Fig. 4B). Young’s modulus for the patellar tendon showed no
overall time effect, but a tendency toward a differential retrain-
ing response of reduced modulus in Plc compared with GH was
observed (P  0.07; Fig. 4C). All other tendon biomechanical
parameters (tendon deformation, strain, or stress throughout
the immobilization and retraining period) were unchanged in
both groups (Table 2).
Tendon Fibrillar Morphology
Fibril volume fraction, fibril density, mean fibril diameter,
and mean fibril area did not differ between GH or Plc at any
time points and did not change over the time course of
immobilization and retraining (Fig. 5, A–D).
Quadriceps Muscle CSA and Maximal Muscle Strength
After immobilization, quadriceps muscle CSA decreased
more in Plc compared with GH (GH: 4.1 
 1.9%; Plc:
9.2 
 1.8%; P  0.05; Fig. 6A). During retraining, the
quadriceps muscle CSA returned to baseline values in both
groups already after 2 wk of training, with a further increase in
GH compared with Plc after 6 wk of training (GH: 9.4
 2.1%;
Plc: 3.1 
 1.3%, relative to baseline; P  0.05; Fig. 6A). At
baseline, there was no difference in quadriceps strength be-
tween the GH and Plc groups. After 2 wk of immobilization,
maximal quadriceps strength was reduced to the same degree
in both groups (GH:39
 4.7%; Plc:29
 5.9%; P 0.01;
Fig. 6B), and both groups regained their muscle strength during
retraining, with no differences between groups (Fig. 6B).
Muscle and Tendon Extracellular Matrix mRNA IGF-1Ea/Ec
and Collagen 1A1/3A1 Expression
Muscle. Both a time effect and a group interaction were seen
in the skeletal muscle gene expression (P  0.001). IGF-1Ea
and IGF-1Ec mRNA increased after 2 wk of immobilization
and subsequent retraining in the GH group, which demon-
Table 1. Changes in body composition (DEXA) baseline vs.
postintervention (2 wk of immobilization and 6 wk of
rehabilitation)
Changes in body composition
GH (n  6) Plc (n  6)
Mean SE Mean SE
Weight (kg), baseline 76.0 2.4 79.9 4.4
Weight (kg), postintervention 77.0 1.9 80.7 4.4
% Fat total, baseline 23.5 0.7 24.2 3.4
% Fat total, postintervention 19.4* 1.2 25.1 3.2
Total FM (kg), baseline 17.1 0.7 19.0 3.4
Total FM (kg), postintervention 15.4* 1.4 20.1 3.3
Total LBM, baseline 55.7 1.8 57.8 1.5
Total LBM, postintervention 59.3* 1.2 57.5 1.2
Changes in body composition (DEXA) baseline vs. postintervention (2 wk
of immobilization and 6 wk of rehabilitation in elderly men (n  12) with
either recombinant human growth hormone (rhGH; n 6) or placebo (Plc; n
6). All values are means 
 SE. GH, growth hormone group; FM, fat mass;
LBM, lean body mass. Post intervention  2 wk of immobilization  6 wk of














Fig. 3. Circulating serum concentrations of IGF-1 after 2 wk of immobilization
and 6 wk of retraining in elderly men (n  12) with either rhGH (n  6) or
placebo (n  6). Data are geometric means 
 SE. *Significant time effect
difference compared with baseline (P  0.001). $Significant group effect of
GH vs. placebo within time point (P  0.01).
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strated greater changes than Plc (P  0.01; Fig. 7, A and B).
There were no changes in IGF-1Ea and IGF-1Ec in Plc fol-
lowing immobilization, but increased IGF-1Ec mRNA was
seen after 6 wk of retraining (P  0.05; Fig. 7A). Relative to
baseline and Plc, GH supplementation increased mRNA
COL1A1 and COL3A1 in muscle following immobilization
and during retraining (P  0.01; Fig. 7, C and D).
Tendon. No time or group interactions were observed for
tendon IGF-1Ea, COL1A1, and COL3A1 mRNA expression
after 2 wk of immobilization with GH supplementation or Plc
supplementation, respectively (Fig. 7, E–G). IGF-1Ec mRNA
concentration was below the detection limit in the majority of
the tendon biopsies and no further analysis was made on the
samples. Furthermore, no significant differences in LOX,
MMP-2, MMP-9, and decorin mRNA expression were ob-
served compared with baseline or between the groups follow-
ing the 2-wk immobilization period (Fig. 8, A–D). Due to the
effect of repeated biopsies on tendon, no further analysis was
made on mRNA expression during the retraining phase.
DISCUSSION
The main findings in the present study were that GH admin-
istration stimulated both local IGF-1 and collagen expression
in skeletal muscle of elderly individuals, which likely contrib-
uted the greater tendon stiffness observed in GH-supplemented
individuals compared with nonsupplemented individuals fol-
lowing 2 wk of lower limb immobilization succeeded by 6 wk
of rehabilitation. This effect was present despite the lack of a
differential effect of GH supplementation on muscle strength
during the same time period.
GH and Changes in Tendon Tissue
In the present study, no significant change in tendon size was
detected with immobilization, and a rise was found during
rehabilitation, and this rise was more pronounced during reha-
bilitation in the presence of GH administration (GH: 8%; Plc:
3%; Fig. 4A). The fact that an effect of immobilization could
not show any change in tendon size is in agreement with recent
human studies in young and elderly (14, 17, 70). However, due
to the small sample size, it cannot fully be excluded that an
effect of immobilization upon tendon size, fibril size or density
could have been missed. The increase in tendon size in re-
sponse to subsequent reloading also conforms to previous
findings, where long-term strength training or habitual loading
appears to be associated with an increase in tendon size (16, 40,
68). In addition to a positive effect on tendon size following the
period of rehabilitation, GH also led to altered biomechanical
tendon properties reflected by elevated tendon stiffness, with
GH supplementation vs. no supplementation (Fig. 4B). The
difference in stiffness and modulus between the two groups
following rehabilitation (Fig. 4, B and C) is likely to be






































Fig. 4. Changes in patellar tendon CSA and biomechanical properties follow-
ing 2 wk of immobilization and 6 wk of retraining in elderly men (n 12) with
either rhGH (n  6) or placebo (n  6a). A: patellar tendon CSA, time effect
(P  0.05); group interaction (P  0.05). B: patellar tendon stiffness, no
overall time effect; group interaction (P  0.05). C: patellar tendon Young
modulus, no overall time effect; group interaction (P  0.07). Data are means 

SE. *Significant time effect difference compared with baseline (both groups;
P  0.05). $Significant group effect difference between GH and Plc within time
point (P  0.05). aBiomechanical data (stiffness and modulus) could only be
obtained for four participants in Plc group post-immob and after 2 wk of training.
Table 2. Changes in tendon biomechanical properties during immobilization and rehabilitation
GH (n  6) Plc (n  6)
Baseline
2 wk
immob 	, % 2 wk train 	, % 6 wk train 	, % Baseline
2 wk
immob 	, % 2 wk train 	, % 6 wk train 	, %
Deformation, mm 1.85 
 0.2 1.74 
 0.2 0.3 
 12.4 1.83 
 0.2 2.8 
 12.4 1.52 
 0.1 14.1 
 7.8 1.45 
 0.1 1.52 
 0.2 9.5 
 19.4 1.62 
 0.2 17.9 
 23.6 1.74 
 0.2 23.9 
 16.1
Strain, % 4.3 
 0.5 4.1 
 0.4 3.4 
 13.0 4.2 
 0.5 2.0 
 12.4 3.5 
 0.3 13.5 
 7.8 3.25 
 0.4 3.5 
 0.5 13.5 
 20.4 3.9 
 0.5 22.2 
 23.9 4.0 
 0.5 27.4.6 
 19.5
Stress, MPa 20.1 
 2.3 20.1 
 2.3 0.3 
 2.5 19.7.
2.0 1.3 
 1.9 19.3 
 2.2 3.6 
 2.3 22.4 
 2.7 22.7 
 2.7 1.5 
 1.9 22.2 
 2.9 1.9 
 1.5 21.3 
 2.7 5.0 
 2.3
Tendon biomechanical properties following 2 wk of immobilization and 6 wk of retraining in elderly men (n  12) with either rhGH (n  6) or Plc (n 
6). All values are means
 SE. 2 wk immob, 2 wk of immobilization; 2 wk train, 2 wk of retraining; 6 wk train, 6 wk of retraining; 	, average of relative changes
(%).Biomechanical data could only be obtained for four participants in the Plc group postimmob and after 2 wk of training. *Significant time effect difference
compared with baseline (P  0.05). §Significant group effect difference between GH and Plc within time point (P  0.05).
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CSA over the entire study period (Fig. 4A). The mechanism
behind this effect of GH on tendon CSA and stiffness during
rehabilitation is presently unknown but might be due to the fact
that GH increases sIGF-1 levels and that local IGF-1 and
collagen expression may have been stimulated in the tendon
during the phase of retraining, as previously demonstrated in
young healthy men (20). Due to a repeated biopsy effect, which
yields substantial amounts of gene upregulation due to the
procedure of biopsy sampling itself, it was not possible to
analyze tendon IGF-1 and collagen expression during the
rehabilitation phase. Notably, fibril size or density did not
change during the intervention (Fig. 5). This could indicate that
the enlargement of the tendon CSA with GH is due to accu-
mulation of other extracellular matrix substances or that the
GH led to neoformation of collagen fibrils with morphological
characteristics that on average resembled the fibrils already
present within the tendon. Regardless, the findings from the
present study suggest that an increase in sIGF-1 level in elderly
via GH administration (Fig. 3) stimulates tendon tissue prolif-
eration (Fig. 4A), which indicates that the GH/IGF-I axis likely
was involved in the concurrent adaptation in tendon mechan-
ical properties (Fig. 4, B and C).
The reduced response in tendon stiffness in the Plc group
compared with the GH group is in accordance with a recent
study on young men (9). The study on young men showed that
GH administration maintained both tendon stiffness and mod-
ulus compared with control during a period of inactivity (9).
Furthermore, tendon stiffness increased with GH, with no
changes in Plc during 6 wk of retraining together with a larger
increase in tendon CSA size (GH: 16% vs. Plc: 11%) (9). The
reason for this effect of GH on tendon stiffness is presently
unknown. Alterations in collagen cross-linking as a result of an
increase in the expression of the enzyme lysyl oxidase (LOX)
within the tendon have been suggested in young individuals
(9). Cross-links are a major contributor in stabilizing collagen
molecules that positively affects intermolecular force transduc-
tion and therefore play an important role in mechanical prop-
erties of the tendon (4, 5). Two types of cross-links have been
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Fig. 5. Changes in patellar tendon fibril
morphology after 2 wk of immobilization
and after 6 wk of retraining in elderly men
(n  12) with either rhGH (n  6) or
placebo (n  6). A: tendon fibril density
(no./m2). B: volume fraction (tendon).
C: tendon mean fibril area (nm2). D: tendon
mean fibril diameter (nm). No time effect or
group interactions were seen within time
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Fig. 6. Changes in quadriceps muscle CSA and maximal isometric strength
following 2 wk of immobilization and 6 wk of retraining in elderly men (n 
12) with either rhGH (n  6) or placebo (n  6). A: quadriceps muscle CSA,
time effect (P  0.01); group interaction (P  0.05). B: maximal isometric
muscle strength, time effect (P 0.001); no overall group interaction. Data are
means 
 SE. *Significant time effect difference compared with baseline (P 
0.05). $Significant group effect difference between GH and Plc within time
point (P  0.05).
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described, enzymatic and nonenzymatic cross-links (4, 5), and
LOX is known to be associated with the formation of enzy-
matic cross-links (60, 71), which has been shown to be in-
creased by GH supplementation in young men (9). However,
no longitudinal changes in LOX were observed in the present
study (Fig. 8A). Again, it has to be underlined that only a
limited number of subjects participated in the present study,
and it cannot be precluded that the large scatter in the data is
limiting a solid conclusion. Increased IGF-I levels have been
shown in other experiments to be associated with an overex-
pression of LOX along with an increase in enzymatic cross-
link formation (61). In a study on rat vascular cells grown on
matrices, IGF-I (plus hyaloronic acid fragments) resulted in an
increased density of cross-links within cell layers (43). Fur-
thermore, that notion of IGF-I is indirectly supported by a
study in experimental rats, where application of a mixture of
IGF-I and FGF-2 resulted in increased LOX expression in the
oral connective tissues (77).
GH and Changes in Muscle CSA
In the present study, muscle CSA declined in the Plc group
during immobilization, which was not the case when GH was
administrated (GH: 4% vs. Plc: 9%; Fig. 6A). Even though
no significant decrease in muscle size was seen in GH during
immobilization, maximal muscle strength declined to a similar
extent in both groups (GH: 39%, Plc: 29%; Fig. 6B).











































































































































Fig. 7. Skeletal muscle and tendon IGF-1 and
collagen (COL) mRNA expression following 2
wk of immobilization and 6 wk of retraining
(muscle) in elderly men (n  12), with either
rhGH (n  6) or placebo (n  6). A: IGF-1Ea
mRNA (muscle), time effect (P  0.001);
group interaction (P  0.001). B: IGF-1Ec
mRNA (muscle), time effect (P  0.001);
group interaction (P  0.001). C: COL 1A1
mRNA (muscle), time effect (P  0.001);
group interaction (P  0.001). D: COL 3A1
(muscle), time effect (0.001); group interaction
(0.001). E: IGF-1Ea mRNA (tendon), no over-
all time effect or group interaction (P  0.05).
F: COL 1A1 mRNA (tendon), no overall time
effect or group interaction. G: COL 3A1 (ten-
don), no overall time effect or group interac-
tion. Data are geometric means 
 SE. *Sign-
ficant time effect difference compared with
baseline (P  0.01). $Signficant group effect
between GH and Plc within time point (P 
0.01).
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periods (weeks) of inactivity have previously been reported in
elderly individuals (32, 41, 42, 73). A possible explanation for
the greater loss of muscle strength compared with muscle mass
observed in the present study could be attributed by a decline
in neuromuscular activity (67, 73). However, we did in the
present study not determine the neuromuscular activity. Fur-
thermore, we did only determine the anatomical CSA and not
the physiological CSA, a parameter which is better correlated
to the strength than the anatomical CSA (12, 57). During the
subsequent phase of rehabilitation, both groups regained mus-
cle mass and muscle strength, with a greater increase in muscle
CSA observed with GH supplementation (GH: 9% vs. Plc: 3%;
Fig. 6A). Recent studies have indicated that elderly individuals
may have a reduced ability to regain the loss in muscle mass
induced by short-term immobilization during the subsequent
phase of retraining (32, 73). This was, however, not the case in
the present study, where the participants in both the GH and the
Plc groups demonstrated a full recovery in muscle CSA and
contractile capacity (MVC) during the 6 wk of retraining.
These disparate findings could arise from study differences in
the duration of immobilization and retraining, respectively,
and/or different muscle assessment procedures employed [an-
atomical muscle CSA obtained by MRI (present study) vs.
myofiber CSA obtained by muscle biopsy sampling (32, 73)].
Furthermore, possible differences in the physical activity status
of the experimental subjects (i.e., different levels of inactivity
before inclusion) may have resulted in different study out-
comes.
As one of the important findings in the present study, the loss
of skeletal muscle mass in response to inactivity in the elderly
seems to be attenuated by administration of GH in the present
study (Fig. 6A). This indicates that increased GH/IGF-I axis
activity via elevated local IGF-1 inhibits the effect of inactivity
on skeletal muscle in elderly subjects. However, since no
difference in maximal muscle strength could be detected be-
tween GH-supplemented and nonsupplemented subjects, it
cannot be excluded that the enhanced gain in muscle size
observed in the GH group could be due to intramuscular water
retention rather than to muscle growth per se, as previously
described (15, 44, 63). This notion is supported by other human
studies, where no effect of GH on myofibrillar protein synthe-
sis was found (20, 44, 79). However, yet other studies have
demonstrated GH administration in elderly individuals to result
in increased muscle volume (63, 78) or improved mechanical
muscle function (44, 58, 63, 74). At present, only a single study
in healthy elderly subjects has reported muscle mass and
muscle strength to increase after GH administration (63, 78).
GH has earlier been used in intensive care patients, causing
protein retention both in patients receiving low-dose GH (23,
82) and supraphysiological GH doses (76, 83). The positive
effect on muscle protein synthesis is supported by a study in
elderly women receiving short-term GH or IGF-1 treatment
resulting in an elevated muscle protein synthesis and increased
net whole body protein synthesis (11). These findings indicate
that GH may in part counteract the net muscle loss induced by
short-term periods of inactivity. Nevertheless, since muscle
strength was not influenced by GH in the present and others
studies (44, 63, 74), the possibility exists that the present
superior gains in muscle CSA with GH may mainly have been
due to fluid retention, which is a known side effect by GH
supplementation (15, 44, 63).
GH and Body Composition
In the present study, 8 wk of GH supplementation led to
decreases in total FM by 10% and LBM by 7%, with no
































































































Fig. 8. Tendon LOX, MMP-2 and -9, and decorin mRNA expression following
2 wk of immobilization in elderly men (n  12), with either rhGH (n  6) or
placebo (n  6). A: LOX mRNA (tendon). B: MMP-2 mRNA (tendon).
C: MMP-9 mRNA (tendon). D: decorin mRNA (tendon). Data are geometric
means
 SE. No overall time effect or group interaction were seen within time
points.
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accordance with previous reports showing that GH adminis-
tration reduces total fat mass and increases lean body mass (45,
58, 63). GH seems to be a strong lipolytic agent (37, 54), and
GH administration has been found to reduce total FM in GHD
patients (13, 66), young obese men (36, 51), and elderly
healthy men (8, 29, 58). DXA-based methods used for deter-
mining changes in lean body mass are not capable of distin-
guishing fluid retention from myofibrillar muscle tissue accu-
mulation, and therefore we cannot rule out that the present
increases in LBM observed with retraining and concurrent GH
administration were at least in part due to fluid retention.
Indirectly supporting this notion, increases in lean body mass
evoked by 12 wk of GH administration in young healthy men
were found to rapidly disappear after 9 days of GH discontin-
uation (45).
GH and mRNA Extracellular Matrix Expression in Skeletal
Muscle and Tendon Connective Tissue
GH administration was associated with elevated local IGF-I
expression and collagen expression in skeletal muscle during
the periods of inactivity and rehabilitation (Fig. 7, A–D). This
association between GH and local IGF-1/collagen expression
failed to be observed in the patellar tendon, which is probably
due to large variation in the limited samples obtained (Fig. 7,
E–G). Furthermore, it has to be noted that, in the present study,
we only determined mRNA expression and not the local
protein concentration of IGF-I, and that we did not measure
IGF-I binding proteins. Thus we are not able to directly
evaluate the local concentration of free IGF-I. Previous ani-
mals studies have demonstrated GH to stimulate IGF-1 and
collagen expression in connective tissue, where changes in the
level of physical activity were associated with a change in
IGF-I and collagen expression (31). Likewise, in humans, it
has been found that GH administration led to increased expres-
sion of both IGF-I and collagen in muscle and tendon, which
occurred in a parallel manner (20). This is further supported by
recent data in young healthy men where GH administration
clearly leads to increased IGF-I and collagen expression in the
musculo-tendinous tissue during short-term immobilization
and retraining (9).
In conclusion, GH administered in healthy, elderly individ-
uals appears to attenuate muscle volume loss during short-term
immobilization and stimulates muscle growth during subse-
quent retraining due to either water retention or muscle tissue
maintenance. At the same time, GH administration was found
to stimulate collagen expression, tendon size, and stiffness
during the rehabilitation phase following short-term inactivity.
The present data indicate that GH can influence the connective
tissue metabolism in musculo-tendinous tissue and tendon
biomechanical properties during short-term immobilization
and subsequent rehabilitation in elderly humans.
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